Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J - LARVOL DELTA

Risk of lymphoma with antimetabolite and biologic combinations: A pharmacovigilance analysis using the FDA adverse event reporting system database (ASH 2025) - "Our study compared combinations of antimetabolites—such asmethotrexate (MTX), mercaptopurine (6-MP), and azathioprine (AZA)—with anti-TNF agents includinginfliximab, adalimumab, certolizumab, and golimumab, to determine which regimens were most stronglyassociated with lymphoma. Clinicians should carefully weigh the risks and benefits of combination immunosuppressivetherapy, especially when prescribing infliximab with MTX or 6-MP, given the observed synergistic increasein risk for lymphoma."

Adverse events • Hematological Malignancies • Immunology • Lymphoma • ROR1

Haploidentical donor regulatory T cells and memory T cells are safe and effective in children with refractory graft-versus-host disease with concurrent viral infections (ASH 2025) - "All patients had received multiple lines of priorIST, including glucocorticosteroids, cyclosporine, and biologics (tocilizumab,infliximab, abatacept, etarnecept, vedolizumab)...Nine patients recieved lymphodepletion with cyclophosphamideat 400 mg/m2... Combined haploidentical Treg and memory T cell therapy, with memory T cellsgenerated solely by flow cytometry-based sorting, is feasible and safe in pediatricpatients with refractory GVHD and viral infections. This approach resulted incomplete IST withdrawal and GVHD control in the majority of evaluable patients at 1year. The promising outcomes in immune reconstitution and viral control supportfurther clinical investigation of this integrative cellular strategy for high-risk pediatrictransplant recipients."

Clinical • Acute Graft versus Host Disease • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Immunology • Infectious Disease • CD8 • FOXP3 • IL2RA • IL7R

Anti-CD19 chimeric antigen receptor T-cell therapy for patients with non-Hodgkin's lymphoma and concurrent autoimmune disease (ASH 2025) - "methotrexate, hydroxychloroquine (HCQ),azathioprine); 9 required biologic/targeted DMARD (ex. adalimumab, etanercept, risankizumab,infliximab, rituximab).DMARDs were weaned prior to CART however 9 pts (37.5%) remained on AID tx at the time of cellcollection, including HCQ (n=4), sulfasalazine/mesalamine (n=2), and 1 each of prednisone, colestipol,sulfasalazine, and apremilast... In this single center study of pts receiving CART for NHL we found no difference in responserates nor survival outcomes in pts with or without AID and therefore propose that AID should notpreclude the use of CART. Lower severity of ICANS was seen in AID pts, though additional study withlarger cohorts is required. The majority of pts were able to taper off AID tx prior to CART, while HCQ wasable to be safely continued throughout CART collection with no apparent effect on CART efficacy."

CAR T-Cell Therapy • Clinical • Ankylosing Spondylitis • B Cell Non-Hodgkin Lymphoma • CNS Disorders • Dermatology • Dermatomyositis • Gastroenterology • Hematological Disorders • Hematological Malignancies • Immunology • Inflammatory Arthritis • Lymphoma • Myasthenia Gravis • Myositis • Non-Hodgkin’s Lymphoma • Psoriasis • Rheumatoid Arthritis • Rheumatology • Seronegative Spondyloarthropathies

P017 A multifaceted case of pyoderma gangrenosum: insights into diagnosis and management in the presence of comorbid conditions. (PubMed, Br J Dermatol) - "She initially presented with a large ulcerative lesion that was misdiagnosed as a fungal infection and treated unsuccessfully with terbinafine...The patient's treatment journey involved multiple immunosuppressive therapies, such as prednisolone and ciclosporin, although ciclosporin was later discontinued due to kidney complications. She was also treated with mycophenolate mofetil, which was halted after it aggravated her diverticular disease, and with dapsone, which was eventually stopped due to liver-related concerns...She is currently under close, multidisciplinary monitoring and is awaiting approval for biologic therapy with risankizumab, which her gastroenterology team favours over infliximab because of liver concerns...Biologic therapies, although currently restricted, represent a promising option for refractory PG. Continuous collaboration among specialists, careful monitoring of treatment impacts on comorbidities, and further research into biologic efficacy..."

Journal • Autoimmune Hepatitis • Dermatology • Gastrointestinal Disorder • Hematological Disorders • Immunology • Infectious Disease • Inflammation • Nephrology • Pain • Pyoderma Gangrenosum • Renal Disease • Septic Shock • Thrombocytopenia

BI32 Something fishy about that ulcer: a leg ulcer on an immunocompromised scuba diver. (PubMed, Br J Dermatol) - "He had a history of psoriatic arthritis, on dual immunosuppression for the past 5 years with methotrexate and adalimumab...He received penicillin antibiotics, topical steroids and mupirocin cream from his general practitioner. He was switched from adalimumab to infliximab for a presumed diagnosis of pyoderma gangrenosum by his treating rheumatology team...His immunosuppression is on hold, both ulcerated lesions continue to slowly enlarge and he remains under close review. This case demonstrates the importance of a full medical and social history, including hobbies and travel, in all patients on immunosuppressive therapy, as they are at risk of atypical infections and presentations."

Journal • Hepatitis B • Hepatitis C • Hepatology • Human Immunodeficiency Virus • Immunology • Infectious Disease • Inflammation • Inflammatory Arthritis • Oncology • Pain • Psoriasis • Psoriatic Arthritis • Pyoderma Gangrenosum • Rheumatology • Seronegative Spondyloarthropathies • Varicella Zoster • IFNG

P121 Treatment with semaglutide improves the systemic inflammatory burden associated with hidradenitis suppurativa. (PubMed, Br J Dermatol) - "The majority of patients (n = 54) had Hurley stage II disease, with 10 patients classified as Hurley stage III and 5 as Hurley stage I. Twenty-two patients were established on adalimumab with two on infliximab. Other biologics prescribed alongside semaglutide included brodalumab (n = 8) and secukinumab (n = 1). Nineteen patients were coprescribed metformin, and for 16 patients rescue antibiotics including rifampicin and clindamycin...Semaglutide can improve not only metabolic control, weight, flare frequency and quality of life, but also systemic inflammation and thus health outcomes (Lyons et al.). Although our findings did not reach statistical significance, the consistent trends observed in inflammatory markers and the established efficacy of semaglutide in weight loss and metabolic improvement suggest that it can enhance health outcomes for this patient population."

Journal • Retrospective data • Dermatology • Genetic Disorders • Hidradenitis Suppurativa • Immunology • Inflammation • Metabolic Disorders • Obesity • Systemic Inflammatory Response Syndrome

BI24 A case of refractory pyoderma gangrenosum successfully treated with upadacitinib. (PubMed, Br J Dermatol) - "The patient also had enteropathic arthritis, initially controlled with infliximab and azathioprine...Initial treatments were unsuccessful, including wound dressings, topical and systemic corticosteroids (intravenous methylprednisolone), topical tacrolimus and antibiotics. Ciclosporin was introduced when she did not respond to escalated doses of infliximab...This case highlights the importance of collaborating with other specialties regarding alternative treatments that are not available for dermatology conditions. Further studies are needed to evaluate the efficacy of Janus kinase inhibitors in PG."

Journal • Crohn's disease • Dermatology • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Immunology • Inflammation • Inflammatory Arthritis • Inflammatory Bowel Disease • Pain • Pyoderma Gangrenosum • Rheumatoid Arthritis • Rheumatology

P088 Janus kinase inhibitor treatment in coexisting atopic dermatitis and irritable bowel disease: real-world experience and therapeutic outcomes. (PubMed, Br J Dermatol) - "Despite the apparent efficacy treating IBD in this series, only two of seven patients (29%) achieved satisfactory cutaneous response to JAKi monotherapy, contrasting with established efficacy data in isolated AD. These findings raise questions about underlying disease mechanisms in this phenotype, warranting further investigation.TableTreatment of seven patients with atopic dermatitis (AD) and irritable bowel disease (IBD) with Janus kinase inhibitors (JAKis)Age (years)Primary indicationBefore JAKi treatmentOn JAKi treatmentDisease statusAD treatmentIBD treatmentJAKi therapyOutcomes50ADEASI 54; UC controlledNoneGuselkumab (stopped)Upadacitinib 24 months (ongoing)EASI 75 achieved (5.1); UC remission22AD, CDEASI 41; CD activeMethotrexate (stopped)Infliximab (stopped)Upadacitinib 4 months (ongoing)EASI 75 achieved (7.4); CD remission29ADEASI 13; UC controlledNoneAZA, allopurinol (stopped)Upadacitinib 8 months (ongoing)EASI 10.3; added methotrexate (6 months), switched to..."

Journal • Real-world evidence • Alopecia • Atopic Dermatitis • Crohn's disease • Dermatitis • Dermatology • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Herpes Zoster • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis • Varicella Zoster

P029 Infliximab-induced lupus panniculitis in hidradenitis suppurativa: a case report. (PubMed, Br J Dermatol) - "We present the case of a 49-year-old woman with hidradenitis suppurativa developing infliximab-induced lupus panniculitis 8 years into her treatment. This is longest length of time between TNF-α inhibitor initiation and lupus panniculitis recorded and is the only case developing in a nonrheumatological patient."

Journal • Cutaneous Lupus Erythematosus • Dermatology • Hidradenitis Suppurativa • Immunology • Inflammatory Arthritis • Lupus • Oncology • Rheumatology

O07 Serious infection risk with systemic treatments for psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). (PubMed, Br J Dermatol) - "Inclusion criteria were adults who received at least one of the biologics, apremilast or conventional nonbiologics (acitretin, ciclosporin and methotrexate) for ≥ 6 months. All biologics licensed for psoriasis were analysed except for infliximab, which had higher prescription criteria...The certolizumab group had a low mean age of 37.4 years (SD 10.3), the ustekinumab group had a significantly longer median treatment duration of over 4 years (IQR 1.83-6.73), and more patients in the ixekizumab (42.6%) and certolizumab (40.6%) groups had concomitant psoriatic arthritis...IRs (95% CIs) of other tumour necrosis factor-α inhibitors were 15.7 (14.5-17.1) for adalimumab and 16.7 (13.8-20.0) for etanercept. For interleukin-17 inhibitors the IRs (95% CIs) were 18.4 (15.9-21.2) for secukinumab, 7.63 (0.92-27.6) for bimekizumab, 14.5 (7.73-24.8) for brodalumab and 18.5 (14.0-24.0) for ixekizumab. For interleukin-23 inhibitors the IRs (95% CIs) were 13.5 (9.97-17.8) for guselkumab,..."

Journal • Observational data • Dermatology • Immunology • Infectious Disease • Inflammatory Arthritis • Oncology • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • IL12A • IL17A

P091 Posterior reversible encephalopathy syndrome (PRES) presenting in a patient with psoriasis receiving ustekinumab. (PubMed, Br J Dermatol) - P3 | "Prochlorperazine 5 mg three times daily and amlodipine 10 mg once daily were commenced and ustekinumab suspended...PRES has been described in patients using adalimumab, infliximab and ustekinumab, most commonly in the context of inflammatory bowel disease...However, it is important that clinicians are aware of this rare debilitating neurological adverse event, so prompt withdrawal of possible triggers including biologic agents can be made to facilitate neurological recovery. The half-life of ustekinumab is problematic for prompt withdrawal and there remain questions regarding ongoing management of the patient's inflammatory dermatosis and arthritis, as case reports document worsening of PRES on reintroduction of traditional immunosuppressive systemic agents."

Journal • Cardiovascular • CNS Disorders • Dermatology • Epilepsy • Gastroenterology • Gastrointestinal Disorder • Hypertension • Immunology • Inflammation • Inflammatory Arthritis • Inflammatory Bowel Disease • Pain • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

BG08 Drug-induced colitis secondary to dupilumab prescribed for pompholyx eczema-bullous pemphigoid overlap: a case report. (PubMed, Br J Dermatol) - "Improvement in bowel symptoms necessitated withdrawal of dupilumab and commencement of infliximab 5 mg kg-1. They have remained well controlled 18 months later. This case report describes a rare occurrence of drug-induced colitis secondary to dupilumab and highlights the need for careful observation for adverse effects and prompt intervention."

Journal • Atopic Dermatitis • Bullous Pemphigoid • Dermatitis • Dermatology • Dermatopathology • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis • IL13 • IL4

Preventive and therapeutic effects of co-administration of Bacteroides thetaiotaomicron and infliximab on dextran sodium sulfate-induced colitis in mice. (PubMed, Intest Res) - "This combination also exhibited synergistic improvement in colitis severity in treated mice. These findings underscore the therapeutic potential of B. thetaiotaomicron in IBD, either alone or in combination with infliximab, and support further development of microbiota-based strategies for IBD prevention and treatment."

Journal • Preclinical • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Oncology • MUC2 • OCLN • TFF3 • TNFA

Efficacy of Advanced Therapies as Prophylaxis and for Active Disease in Postoperative Crohn's Disease: A Comprehensive Review. (PubMed, J Clin Med) - "Infliximab and vedolizumab have the strongest evidence for preventing endoscopic recurrence in postoperative Crohn's disease. Adalimumab and ustekinumab are viable alternatives supported by observational and post hoc trial data...Approaches that integrate disease location, clinical risk profiles, and knowledge of underlying immunopathogenic pathways could provide more precise clinical guidance. Finding molecular predictors of recurrence, directly comparing cutting-edge treatments, and integrating precision medicine techniques into standard postoperative care should be the main priorities of future research."

Journal • Review • Crohn's disease • Gastroenterology • Immunology • Inflammatory Bowel Disease • IL23A

Safety profile of TNF- alpha Inhibitors in pediatric patients: A post-marketing surveillance study based on the FAERS database. (PubMed, PLoS One) - "This study systematically evaluated the safety profile of tumor necrosis factor-alpha (TNF-α) inhibitors in pediatric patients using data from the U.S. Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) from Q1 2004 to Q3 2024.Through disproportionality analysis of adverse event (AE) reports for infliximab, etanercept, adalimumab, golimumab and certolizumab, we identified 852 significant safety signals spanning 27 system organ classes (SOCs). While these agents remain vital for managing chronic inflammatory diseases, the findings advocate for enhanced clinical vigilance. We propose a tiered monitoring protocol prioritizing infection surveillance (e.g., serial inflammatory markers), systematic injection-site evaluations, and longitudinal organ function assessments, particularly during the initial treatment phase, to optimize therapeutic risk-benefit ratios."

Journal • P4 data • Gastroenterology • Gastrointestinal Disorder • Infectious Disease • Oncology • Pediatrics

Serious Infections in Offspring Exposed to Tumour Necrosis Factor Inhibitors During Pregnancy: Comparison of Timing During Pregnancy and Placental Transfer Ability. (PubMed, Arthritis Rheumatol) - "Overall, TNFi exposure was not associated with serious infections; exploratory signals by timing and placental transfer were imprecise and require confirmation."

Journal • Infectious Disease • Oncology

Hepatitis B reactivation linked to tumor necrosis factor-α inhibitors in rheumatoid arthritis: a systematic review and meta-analysis. (PubMed, Cell Mol Biol (Noisy-le-grand)) - "HBVr rates also varied by TNFi type, with 4% for adalimumab, 3% for etanercept, and 2% for infliximab. Overall, TNFi therapy in HBV-related RA is associated with a low but clinically relevant risk of HBVr, with higher rates in HBsAg-positive patients and modest variation by region and drug type, while antiviral prophylaxis and glucocorticoid use appear to have no significant effect on risk."

Clinical • Journal • Retrospective data • Review • Hepatitis B • Immunology • Infectious Disease • Inflammation • Inflammatory Arthritis • Oncology • Rheumatoid Arthritis • Rheumatology

ZEST: Zymfentra (Infliximab-dyyb) REal World Cohort STudy (clinicaltrials.gov) - P=N/A | N=200 | Recruiting | Sponsor: University of North Carolina, Chapel Hill | Not yet recruiting ➔ Recruiting

Enrollment open • Real-world evidence • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis

Autoimmune-like hepatitis induced by drugs: Still many unanswered questions. (PubMed, World J Hepatol) - "Several drugs, including nitrofurantoin, minocycline, hydralazine, methyldopa and infliximab, have a well-documented capacity to induce DI-ALH. International collaborative studies are needed to further characterize DI-ALH. In this review, we update current controversies, present emerging concepts, and outline future challenges in the diagnosis and management of this complex condition learned so far."

Journal • Review • Autoimmune Hepatitis • Fibrosis • Hepatology • Immunology • Inflammation • Liver Failure

Biomarkers of mitochondrial permeability transition-driven necrosis in the regulation of ulcerative colitis. (PubMed, PeerJ) - "The MPTDN-related genes CASP1 and CASP4 have been identified as potential biomarkers for the diagnosis of UC and are associated with abnormal immune cell infiltration in UC patients. Additionally, CASP1 may serve as a predictor of sensitivity to infliximab therapy."

Biomarker • Journal • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis • CASP1 • CASP4

Rate and predictors of successful antitumor necrosis factor deescalation after dose intensification in inflammatory bowel disease patients: a real-world Greek-Turkish collaborative study. (PubMed, Eur J Gastroenterol Hepatol) - "One quarter of IBD patients requiring intensified anti-TNFa therapie were successfully deescalated to standard dosing, after a median of 16.0 (IQR: 8.0-36.0) months."

Journal • Real-world evidence • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Oncology • Ulcerative Colitis • TNFA

A comparative analysis of biologics market dynamics in 12 countries: (Bio)similar and sustainability. (PubMed, Front Pharmacol) - "Group A consisted of biologics with biosimilars-etanercept, infliximab, rituximab, and trastuzumab, while Group B comprised biologics without biosimilars, including cetuximab, nivolumab, and pembrolizumab. The introduction of biosimilars was significantly associated with reductions in the prices and expenditures of biologics in high-income countries. This underscores the potential role of biosimilars in supporting the long-term sustainability of the healthcare system."

Journal • Oncology

Characterization of Laboratory Studies and Treatments of Interstitial Granulomatous Dermatitis with Arthritis: A Case Report and Review of the Literature (ISDS 2025) - "Methotrexate and hydroxychloroquine were each used in 20% of cases, and biologics were used in 8% of cases. The biologics utilized include adalimumab, infliximab, ustekinumab, and tocilizumab. Response to biologics was overall favorable, with cutaneous symptoms improving to a greater degree than arthralgias."

Case report • Clinical • Review • Dermatitis • Dermatology • Immunology • Inflammatory Arthritis • Musculoskeletal Pain • Rheumatoid Arthritis • Rheumatology • CRP

Utilisation and real-world effectiveness of advanced therapies for inflammatory bowel disease in Middle Eastern populations: a systematic review. (PubMed, BMJ Open Gastroenterol) - "Advanced therapies for IBD appear to be effective in Middle Eastern cohorts; however, the available evidence is methodologically diverse, with substantial heterogeneity in study design, population characteristics and outcome reporting, which limits the ability to draw strong conclusions and highlights the need for further robust evaluation. Prospective, collaborative regional registries are imperative to address these gaps and inform local guidelines."

Journal • Real-world evidence • Review • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Oncology • Pediatrics • Ulcerative Colitis

TNF Inhibitor-Induced Sarcoidosis-Like Lesions in Inflammatory Bowel Disease. (PubMed, United European Gastroenterol J) - "TNF inhibitor-induced sarcoidosis should be considered in inflammatory bowel disease patients with chronic respiratory symptoms or fever after exclusion of mycobacterial infection. Management involves discontinuation of TNF inhibitors and a course of steroids."

Journal • CNS Disorders • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Infectious Disease • Inflammation • Inflammatory Bowel Disease • Oncology • Pulmonary Disease • Sarcoidosis • Ulcerative Colitis